Merit Medical Systems INC

Merit Medical Systems announced second quarter 2026 financial results exceeding expectations, driven by robust revenue growth and improved margins, leading to an upward revision of full-year guidance.

Merit Medical Systems, Inc. announced shareholder approval of its 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, alongside director elections and auditor ratification.

Merit Medical reported Q1 2026 revenue of $381.9 million, up 7% year-over-year, and updated its full-year 2026 financial guidance.

Merit Medical Systems provides a detailed historical revenue breakdown by foundational and therapeutic product categories for 2022-2025.

Merit Medical Systems, Inc. announced the acquisition of View Point Medical, Inc. for approximately $140 million, expanding its therapeutic oncology product line with the OneMark Detection Imaging System.

Merit Medical Systems, Inc. reported better-than-expected fourth quarter and full-year 2025 financial results, alongside optimistic guidance for fiscal year 2026.

Merit Medical Systems Inc. announced a 9.5% increase in net sales for the second quarter of 2026, driven by growth in both foundational and therapeutic product categories.

Merit Medical Systems, Inc. reported increased net sales and gross profit for Q3 2025, alongside a CEO transition and the conclusion of an SEC inquiry.

Merit Medical Systems reports increased net sales for Q2 2025 driven by acquisitions and international demand, but net income and EPS declined due to higher operating expenses and tax rates.

Merit Medical Systems reports a 9.8% increase in revenue and a rise in net income for the first quarter of 2025, driven by strong U.S. demand and strategic acquisitions.

Merit Medical Systems, Inc. announced a 7.8% increase in sales for the third quarter of 2024, reaching $339.8 million, alongside a rise in net income to $28.4 million.

Merit Medical Systems, Inc. announced a 7.1% increase in sales for the six-month period ended June 30, 2024, driven by strong U.S. and international demand.

Merit Medical Systems, Inc. reported robust financial results for the fiscal year ended December 31, 2025, with significant revenue growth and increased profitability driven by strategic acquisitions and strong demand.

Merit Medical Systems has filed an amendment to its annual report to correct the five-year cumulative total return information for NASDAQ Stocks within its original filing.

Merit Medical Systems, Inc. announces a successful fiscal year 2024, marked by significant revenue growth, strategic acquisitions, and advancements in key product areas.

Merit Medical Systems, Inc., a leading manufacturer of medical devices, announced record sales of $1.257 billion for the year ended December 31, 2023, marking a 9.2% increase from 2022, fueled by robust demand in the U.S. and favorable international sales trends.

Merit Medical Systems' Chief Human Resources Officer, Michel J. Voigt, reported a charitable gift of common stock and disposed of shares.

Brian G. Lloyd, Chief Legal Officer of Merit Medical Systems, reported a disposition of 2,000 shares of common stock via a charitable gift.

Merit Medical Systems Director Thomas J. Gunderson exercised stock options for 21,250 shares of common stock on May 20, 2026.

Director Lynne N. Ward was granted 3,457 restricted stock units under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan.

Director Scott R. Ward was granted 3,457 restricted stock units under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan.

Director Thomas J. Gunderson was granted 3,457 restricted stock units under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan.

Merit Medical Systems, Inc. announced record-setting 2025 revenue of $1.516 billion, strong profitability, and a successful CEO transition to Martha G. Aronson, alongside proposals for its 2026 Annual Meeting.

Merit Medical Systems, Inc. announces its 2025 Annual Meeting of Shareholders to be held virtually on May 14, 2025, with key proposals including the election of directors and ratification of the company's executive compensation and auditor appointment.

Merit Medical Systems announces its 2025 Annual Meeting of Shareholders to be held virtually on May 14, 2025, following a year of strong financial results and strategic advancements.

Merit Medical Systems, Inc. announces its annual shareholder meeting to be held on May 15, 2024, outlining proposals for director elections, executive compensation, an incentive plan amendment, and auditor ratification.

Merit Medical Systems is soliciting proxies for its upcoming annual meeting, featuring proposals for director elections, executive compensation, and an increase in shares authorized under its long-term incentive plan.

Vanguard Capital Management, along with its affiliates, has reported beneficial ownership of 5.23% of Merit Medical Systems Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 6.01% in Merit Medical Systems Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G for Merit Medical Systems Inc., reporting 0% beneficial ownership due to an internal corporate realignment.

BlackRock, Inc. has reported an increased beneficial ownership of 14.1% in Merit Medical Systems Inc. common stock, totaling 8,370,301 shares.